Gammacan's Oncology Program Highlighted at International Plasma Protein Congress
March 13 2006 - 6:30AM
Business Wire
At a plenary session addressing attendees of the International
Plasma Protein Congress (IPPC 2006) taking place in Prague on March
7th and 8th, a panel of industry consultants and opinion leaders
discussed the evolving world-wide plasma markets and highlighted
Gammacan's (OTCBB:GCAN) efforts in the field. In the course of the
presentation, the addition on new plasma derived products was
identified as among the key drivers for the continued growth of the
plasma derived protein market. Patrick Robert of the Marketing
Research Bureau, an industry thought leader and publisher of the
monthly "International Blood/Plasma News," specifically mentioned
Gammacan's (OTCBB: GCAN) Oncology Program as "an example of an
effort that would contribute to the growth of the IVIg market."
Vered Caplan, CEO of Gammacan commented: "We were pleasantly
surprised by this unexpected recognition of our efforts in the
development of IVIg-derived plasma products for the treatment of a
variety of cancers. This industry endorsement is a clear signal
that lends further support to our ongoing clinical development
programs." About Gammacan Gammacan is focusing on the
commercialization of a revolutionary anti-cancer immunotherapy that
the Company believes will be proven to be effective in reducing the
metastatic spread of a wide range of cancers. Gammacan's proposed
treatment is based on IVIg, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. It works by strengthening the
patient's immune system. Many experts currently view immunotherapy
as a future alternative to today's standard chemotherapy. IVIg is
commonly used to treat certain autoimmune diseases and blood
disorders and to replace the antibodies in people who are unable to
produce them. For more information about Gammacan visit
www.Gammacan.com or call the company's headquarters in Givat
Shmuel, Israel at 972 3 577 4475 or 1-866-308-0396 (from North
America) About International Blood/Plasma News IB/PN is published
by the Marketing Research Bureau, an internationally recognized
market research firm specializing in the collection and analysis of
data and market in the area of plasma-derived and recombinant
protein therapies. More information is available at
www.marketingresearchbureau.com. Safe Harbor Statement: Statements
in this document that are not purely historical are forward-looking
statements. Forward-looking statements in this release include
statements regarding: the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IVIG into an effective treatment.
Actual outcomes and the Company's actual results could differ
materially from those in such forward-looking statements. Factors
that could cause actual results to differ materially include risks
and uncertainties such as the inability to finance the planned
development of the technology, inability to hire appropriate staff
to develop the technology, unforeseen technical difficulties in
developing the technology, inability to obtain regulatory approval
for human use, competitors' therapies proving more effective,
cheaper or otherwise preferable for consumers, inability to market
the product we produce, among other factors, all of which could
among other things, delay or prevent product release or cause our
company to fail. For further risk factors see the risk factors
associated with other early stage medical research and development
companies filed with the SEC on Edgar.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024